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Table I. Evaluation of TNF-a promoter polymorphisms
by Chi-square test under a case/control design
Index patients Controls
with psoriasis Parents (Mainz Data)
n % n % n %
TNF-α –238a
G/G 57 69 127 77 92 93
G/A 26 31 39 24 7 7
A/A 0 0 0 0 0 0
Total 83 166 99
TNF-α –308b
G/G 61 75 112 69 73 74
G/A 18 22 43 27 20 20
A/A 1 1 1 1 6 6
Total 81 162 99
aTest statistics for TNF-α –238: G/A and A/A versus G/G for index patients versus
Mainz controls taken from Ho¨hler et al (1997) gives Chi square of 16.193, p 5 0.001.
bTest statistics for TNF-α –308: G/A and A/A versus G/G for index patients versus
Mainz controls taken from Ho¨hler et al (1997) gives Chi square of 1.147, p 5 0.284.
Table II. Evaluation of TNF-a promoter polymorphisms
by TDT
Transmitted alleles Untransmitted TDTa One-sided
in heterozygous alleles in parents p valueb
index patients
TNF-α –238c
G 15 26 2.95 0.99
A 26 15 0.11
TNF-α –308d
G 24 19 0.58 0.47
A 19 24 0.58 0.97
aThe alpha test version for computing TDT-like likelihood ratio statistics based
on Terwilliger (1995) was used.
bSeparate evaluation of paternal transmission gave for the –238 locus a p value of
0.28 and for the –308 locus a p value of 0.50. Likewise maternal transmission gave
a p value of 0.50 for the –238 locus and a p value of 0.43 for the –308 locus.
cMaximum likelihood estimate of TDT lambda 5 0.64, p value 5 0.10.
dMaximum likelihood lambda 5 0.50, p value 5 0.50.
Table III. Test for Hardy–Weinberg-Equilibrium in the
Mainz control group for the –308 polymorphism
Chi-square (total, DF 5 1) 6.413165
Probability (Chi-square, DF 5 1) 0.011328
Observed G/G 73
Expected G/G 69.59
Chi-square 0.167510
Observed G/A 20
Expected G/A 26.83
Chi-square 1.737921
Observed A/A 6
Expected A/A 2.59
Chi-square 4.507734
Conclusion: There is a significant deviation from a
Hardy–Weinberg-equilibrium in the control group.
validity of the results obtained in the case control study of Ho¨hler
et al (1997), because the design of case control studies allows for
type 1 errors that can occur when the control group does not
truely represent the general population. In contrast, the TDT
circumvents the difficult matching of the control group as it
considers as a control the untransmitted alleles of the parents.
Therefore the TDT is today considered as a powerful instrument
in genetic studies of complex diseases and recently allowed, for
example, the mapping of a locus for autistic disorders (Cook
et al, 1998).
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Reply
Traupe et al have investigated the allele distribution of polymorph-
isms in the promoter of the tumor necrosis factor (TNF)-α gene,
which is encoded within the major histocompatibility complex
(MHC), in patients with familial and sporadic psoriasis. In contrast
to two previously published papers (Arias et al, 1997; Ho¨hler et al,
1997) that reported a highly significant association of familial cases
with type 1 psoriasis with the TNF238.2 allele (A at position –
238), the authors found no association in their study using the
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transmission disequilibrium test (TDT). Considering the small
number of informative proband/parents pairs investigated (39
according to Table I, there appears to be an error in Table II and
in the text, where 41 heterozygotes are stated), we think that the
presented data would deserve a more cautious interpretation.
Psoriasis is a polygenic disease. In the last 3 y a number of
candidate regions have been identified on several chromosomes
(Tomfohrde et al, 1994; Nair et al, 1997; Trembath et al, 1997).
Particularly patients with type 1 psoriasis (positive family history,
disease onset ,40 y) show strong linkage to the MHC on the
short arm of chromosome 6 (Elder et al, 1994). The extended
haplotype Cw6-B57-DR7 is associated with the highest risk of
developing the disease (Schmitt-Egenolf et al, 1993). The TNF238.2
promoter polymorphism is part of this ancestral haplotype.
In the study by Traupe et al there is also significant increase of
the TNF238.2 variant among psoriasis patients compared to the
control group in our own study (15% compared with 3.5%;
p , 0.001). This allele frequency has been confirmed in another
German control population (4.8% in 123 healthy blood donors,
Arias et al, 1997) and a third independent group of controls
investigated by our group. The TNF238.2 allele frequency in the
German population is slightly lower than that reported from Italy
(7%, D’Alfonso and Richiardi, 1994).
In the Traupe study there is also a significant increase of the
TNF238.2 polymorphism among the parents (allele frequency 12%
compared with 3.5%, p , 0.01), which is not surprising because
42 individuals from this group were also suffering from psoriasis.
Unfortunately the authors do not present any data on this subgroup.
The overall lower TNF238.2 allele frequency in the Traupe
study is most likely due to the fact that 49% of the patients were
sporadic cases, whereas in both previous studies only patients with
a positive family history were included. Particularly this patient
group shows a strong association with the MHC (Elder et al, 1994).
The TDT investigates the frequency with which a certain allele
is transmitted to the offspring. Traupe et al found that in 39
informative proband/parents pairs the TNF238.2 allele was trans-
mitted to 63% of the probands (in comparision the TNF308.2
allele was transmitted in only 42% of the cases). Although these
data show segregation of the TNF238.2 polymorphism with
psoriasis they are not statistically significant; however, preferential
Human Epidermal Proopiomelanocortin (POMC) cDNA
Variant is Identical to Mouse POMC cDNA
To the Editor:
We are most concerned about the sequence of the putative variant
of proopiomelanocortin (POMC) in the human epidermis and in
epidermal cells as reported by Can et al (1998). Initially we were
quite surprised by the report of 28 base changes in a small region
of Exon 3 of the variant POMC cDNA compared with the well-
established human POMC cDNA sequence from the pituitary
gland. This number seemed to be a rather unusual amount of
polymorphism in this putative epidermal variant. Upon careful
examination of these 28 base substitutions it was confirmed that
the reported human epidermal POMC cDNA variant is identical
to that reported for mouse POMC cDNA alpha (Uhler and
Herbert, 1983; Uhler et al, 1983; Eberle, 1998). Table 1 presents
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inheritance of the TNF238.2 allele to 60%–70% of the offspring
would be in accordance with our current concept of psoriasis as a
polygenic disease with a disease concordance of 55%–70% among
monozygotic twins, knowing that this allele is just one of several
factors that confers disease susceptibility. In our opinion the number
of informative proband/parents pairs is too small to detect the
disease association with the TNF238.2 allele. Considering the high
percentage of sporadic cases and the small number of informative
proband/parents pairs, we would be interested to know whether
this study design would allow the association of the extended
haplotype Cw6-B57-DR7 with psoriasis, which has been recently
confirmed in a large study using the TDT (Jenisch et al, 1998), to
be detected.
Thomas Ho¨hler
I. Medizinische Klinik und Poliklinik, Johannes Gutenberg-
Universita¨t Mainz, Mainz, Germany
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a comparison between these 28 base changes in human pituitary
POMC cDNA in Exon 3 with the proposed human skin POMC
cDNA variant and mouse POMC cDNA where the proposed skin
variant is identical to the mouse. This result could most likely be
accounted for by polymerase chain reaction errors introduced either
by the mouse pituitary cell line (AtT20) used as a positive control
throughout the in situ hybridization experiments, or from human
skin grafts onto the mice used in this study. It is obvious that
mouse cDNA must have been introduced erroneously into the
human cDNA reactions early in the experimental protocol, con-
sequently leading to the false positive result. Therefore we would
like to point out that the human epidermis and epidermal cells in
culture contain only the POMC cDNA previously established for
the pituitary gland and not a variant as reported by Can et al (1998).
Janis Ancans, Anthony J. Thody, John M. Wood,
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